SCHEMBL640816

SCHEMBL640816

O=C([O-])c1c(Cc2ccccc2)ccc2c1Cc1ccccc1O2.O=C([O-])c1c(Cc2ccccc2)ccc2c1Cc1ccccc1O2.[Ni+2]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
ACSL1 P33121 1/20 0.35
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
HSP90AA1 P07900 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL673696 0.97 MAOA (0.39) MAOAMAOBACSL1HDAC3HDAC4
SCHEMBL11607982 0.97 MAOA (0.39) MAOAMAOBACSL1HDAC3HDAC4
Potassium Ion SCHEMBL7936384 0.97 MAOA (0.39) MAOAMAOBACSL1HDAC3HDAC4
SCHEMBL673859 0.97 MAOA (0.39) MAOAMAOBACSL1HDAC3HDAC4
SCHEMBL672163 0.97 MAOA (0.39) MAOAMAOBACSL1HDAC3HDAC4
SCHEMBL153179 0.97 MAOA (0.39) MAOAMAOBACSL1HDAC3HDAC4
SCHEMBL672205 0.97 MAOA (0.39) MAOAMAOBACSL1HDAC3HDAC4
SCHEMBL4705461 0.90 MAOA (0.43) MAOAMAOBACSL1HSP90AA1TDP1
SCHEMBL28807968 0.86 MAOA (0.40) MAOAMAOBACSL1HSP90AA1TDP1
SCHEMBL640834 0.86 MAOA (0.42) MAOAMAOBACSL1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3969490-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND TIRE COMPONENTS BRIDGESTONE CORP (JP) 2026-03-25 EP disclosed
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-12-25 US disclosed
US-12410263-B2 Modified high-Cis polybutadiene polymer, related methods and rubber compositions BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-09-09 US disclosed
US-12264232-B2 Modified high-cis polybutadiene polymer, related methods and tire components BRIDGESTONE CORPORATION (JP) 2025-04-01 US disclosed
US-20250066516-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME BRIDGESTONE CORPORATION (JP) 2025-02-27 US disclosed
CN-113825777-B Modified high cis polybutadiene polymers, related methods and tire components 株式会社普利司通 2025-01-28 CN disclosed
EP-4495146-A2 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS Bridgestone Americas Tire Operations, LLC (US) 2025-01-22 EP disclosed
EP-4457250-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME Bridgestone Corporation (JP) 2024-11-06 EP disclosed
EP-3966259-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS LLC (US) 2024-10-30 EP disclosed
CN-118574860-A Hydrogenated polybutadiene polymer and rubber composition containing the same 株式会社普利司通 2024-08-30 CN disclosed
WO-2011047021-A1 PROCESSES FOR PREPARATION OF CYCLIC ACYCLIC DIENE COPOLYMER AND RUBBER COMPOSITION BRIDGESTONE CORPORATION (JP) 2011-04-21 WO disclosed
US-20100137520-A1 Branched Polymers and Methods for Their Synthesis and Use BRIDGESTONE CORPORATION (JP) 2010-06-03 US disclosed
US-7585805-B2 polymerization catalyst containing e.g.a combination or reaction product of triisobutylaluminum an alkylating agent, Ni(II) neodecanoate borate as nickel compound, trifluoride/n-hexanol complex as F2 compound and tin tetrachloride as Cl2 compound to polymerize 1,3-butadiene to cis-1,4-polybutadiene BRIDGESTONE CORPORATION 2009-09-08 US disclosed
EP-2066735-A2 BRANCHED POLYMERS AND METHODS FOR THEIR SYNTHESIS AND USE Bridgestone Corporation (JP) 2009-06-10 EP disclosed
US-20080255327-A1 addition polymerization of conjugated polyene monomer in the presence of polymerization catalysts comprising a mixture of a nickel-containing compound, an alkylating agent, a fluorine-containing compound, a carboxylic acid and an alcohol; controlling gelation, branching and molecular weight; efficiency BRIDGESTONE CORPORATION (JP) 2008-10-16 US disclosed
WO-2008045372-A2 BRANCHED POLYMERS AND METHODS FOR THEIR SYNTHESIS AND USE BRIDGESTONE CORPORATION (JP) 2008-04-17 WO disclosed
US-20070117942-A1 Nickel-based catalyst composition BRIDGESTONE CORPORATION 2007-05-24 US disclosed
EP-1788003-A1 Nickel-based catalyst composition Bridgestone Corporation (JP) 2007-05-23 EP disclosed
US-6699813-B2 COMPOSITION THAT IS COMBINATION OF OR REACTION PRODUCT OF LANTHANIDE COMPOUND, ALKYLATING AGENT, NICKEL-CONTAINING COMPOUND, AND OPTIONALLY HALOGEN-CONTAINING COMPOUND THAT INCLUDES ONE OR MORE LABILE HALOGEN ATOMS BRIDGESTONE CORPORATION (JP) 2004-03-02 US disclosed
US-20030176276-A1 Lanthanide-based catalyst composition for the manufacture of polydienes BRIDGESTONE CORPORATION (JP) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS MALT1, INO80C, RTCB MAOA 3771/4885MAOB 2373/4885ACSL1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.